Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/bjc.2017.36 http://scihub22266oqcxt.onion/10.1038/bjc.2017.36 C5379148!5379148!28222073     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Cancer 2017 ; 116 (7): 884-92 Nephropedia Template TP {{tp|p=28222073|t=2017. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours |pdf=|usr=}}{{28222073}} gab.com Text A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours JO: Br J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=28222073 #FOAvip Background:: This study evaluated safety, pharmacokinetics, and clinical activity of intravenous and oral rucaparib, a poly(ADP-ribose) polymerase inhibitor, combined with chemotherapy in patients with advanced solid tumours. Methods:: Initially, patients received escalating doses of intravenous rucaparib combined with carboplatin, carboplatin/paclitaxel, cisplatin/pemetrexed, or epirubicin/cyclophosphamide. Subsequently, the study was amended to focus on oral rucaparib (once daily, days 1?14) combined with carboplatin (day 1) in 21-day cycles. Dose-limiting toxicities (DLTs) were assessed in cycle 1 and safety in all cycles. Results:: Eighty-five patients were enrolled (22 breast, 15 ovarian/peritoneal, and 48 other primary cancers), with a median of three prior therapies (range, 1?7). Neutropenia (27.1%) and thrombocytopenia (18.8%) were the most common grade ?3 toxicities across combinations and were DLTs with the oral rucaparib/carboplatin combination. Maximum tolerated dose for the combination was 240?mg per day oral rucaparib and carboplatin area under the curve 5?mg?ml?1?min?1. Oral rucaparib demonstrated dose-proportional kinetics, a long half-life (?17?h), and good bioavailability (36%). Pharmacokinetics were unchanged by carboplatin coadministration. The rucaparib/carboplatin combination had radiologic antitumour activity, primarily in BRCA1- or BRCA2-mutated breast and ovarian/peritoneal cancers. Conclusions:: Oral rucaparib can be safely combined with a clinically relevant dose of carboplatin in patients with advanced solid tumours (Trial registration ID: NCT01009190). Twit Text FOAVip A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours ????Br J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=28222073 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28222073 #FOAvip English Wikipedia <ref>{{Cite pmid|28222073}}</ref> A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours #MMPMID28222073 Wilson RH; Evans TJ; Middleton MR; Molife LR; Spicer J; Dieras V; Roxburgh P; Giordano H; Jaw-Tsai S; Goble S; Plummer R Br J Cancer 2017[Mar]; 116 (7): 884-92 PMID28222073show ga Background:: This study evaluated safety, pharmacokinetics, and clinical activity of intravenous and oral rucaparib, a poly(ADP-ribose) polymerase inhibitor, combined with chemotherapy in patients with advanced solid tumours. Methods:: Initially, patients received escalating doses of intravenous rucaparib combined with carboplatin, carboplatin/paclitaxel, cisplatin/pemetrexed, or epirubicin/cyclophosphamide. Subsequently, the study was amended to focus on oral rucaparib (once daily, days 1?14) combined with carboplatin (day 1) in 21-day cycles. Dose-limiting toxicities (DLTs) were assessed in cycle 1 and safety in all cycles. Results:: Eighty-five patients were enrolled (22 breast, 15 ovarian/peritoneal, and 48 other primary cancers), with a median of three prior therapies (range, 1?7). Neutropenia (27.1%) and thrombocytopenia (18.8%) were the most common grade ?3 toxicities across combinations and were DLTs with the oral rucaparib/carboplatin combination. Maximum tolerated dose for the combination was 240?mg per day oral rucaparib and carboplatin area under the curve 5?mg?ml?1?min?1. Oral rucaparib demonstrated dose-proportional kinetics, a long half-life (?17?h), and good bioavailability (36%). Pharmacokinetics were unchanged by carboplatin coadministration. The rucaparib/carboplatin combination had radiologic antitumour activity, primarily in BRCA1- or BRCA2-mutated breast and ovarian/peritoneal cancers. Conclusions:: Oral rucaparib can be safely combined with a clinically relevant dose of carboplatin in patients with advanced solid tumours (Trial registration ID: NCT01009190). äA phase I study of intravenous and oral rucaparib in combination with (epmc).pdf DeepDyve Pubget Overpricing